"the potential for returns are phenomenal"

Are Investors Allergic to TBI Research?

A recent article in BioWorld Today by Donna Young discuses the difficulties that traumatic brain injury (TBI) research faces when looking for potential investors.

It would seem that financial backers are turned off by past drug failures that are brain injury specific - strokes, brain illnesses and brain trauma. Harry Tracy who runs NI Research, a neurological focused consulting firm, cites 50 stroke drugs that failed over the past 10 years. Tracy says that this is because of the difficulty in conducting clinical trials as there are a variety of reactions to not only the drugs but the injuries themselves.

This lack of ready progress, high cost and level of complexity discourages potential investors from TBI research, which detrimentally effects millions every year. Larry Glass, CEO of Neuren Pharmaceuticals Ltd. says that TBI is second only to hemorrhage as a cause of death for soldiers serving in Iraq and Afghanistan.

Glass believes that while there are initial complications and expenses involved, "the potential for returns are phenomenal" which is why his company is partnering with the U.S. Army to develop the drug NNZ-2566. This drug will hopefully work to prevent secondary damage to brain cells, reducing the degree of damage sustained by the initial TBI.

http://www.brainandspinalcord.org/category/blog-categories/latest-research?page=7